Gold prices bounce off 3-week lows; demand likely longer term
In a challenging market environment, Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) stock has touched a new 52-week low, dipping to $14.3. According to InvestingPro analysis, the company maintains a "GOOD" overall financial health score despite current market pressures. This latest price level reflects a significant downturn for the company, which has seen its stock price contract by 57% in the past year. Investors have been cautious, reacting to a combination of company-specific developments and broader market trends that have weighed heavily on the biotechnology sector. InvestingPro data suggests the stock is currently trading below its Fair Value, with analyst targets indicating potential upside. InvestingPro subscribers have access to 8 additional key insights about ARCT’s financial position. The 52-week low serves as a stark indicator of the volatility and the bearish sentiment that has taken hold of Arcturus Therapeutics’ market valuation in recent times, with the stock’s beta of 2.96 reflecting its significant price swings relative to the broader market. Discover comprehensive analysis and more metrics in the Pro Research Report, available exclusively on InvestingPro.
In other recent news, Arcturus Therapeutics reported a significant earnings miss for the fourth quarter of 2024, with earnings per share at -$1.11, falling short of the anticipated -$0.19. The company’s revenue also did not meet expectations, coming in at $22.8 million compared to the forecasted $63.22 million. Additionally, Arcturus’s annual revenue decreased to $152.3 million, a drop of $14.5 million from the previous year. Despite these financial challenges, Arcturus announced a gross profit share of $28 million for its COVID-19 vaccine, CoStave, in Japan, which is part of its collaboration with Meiji and CSL (OTC:CSLLY). The company has received European Union approval for CoStave and is preparing for a Biologics License Application in the United States later this year.
Analyst firm Leerink Partners adjusted its price target for Arcturus, reducing it from $70 to $65, but maintained an Outperform rating, reflecting a positive outlook despite the earnings miss. Arcturus is advancing its rare disease programs, with Phase 2 data for cystic fibrosis and ornithine transcarbamylase deficiency expected by mid-2025. The company remains focused on expanding its therapeutic and vaccine pipelines, with interim data for key programs anticipated in 2025. Arcturus’s strong cash position of $293.9 million as of December 31, 2024, supports its ongoing development efforts.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.